8-K: Travere Therapeutics Submits sNDA to FDA for FILSPARI in FSGS, Seeking Priority Review

Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking traditional approval and priority review for FILSPARI in the treatment of focal segmental glomerulosclerosis (FSGS).

Summary

• Travere Therapeutics announced the submission of a supplemental New Drug Application (sNDA) to the FDA for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).
• The company is seeking priority review for traditional approval.
• The sNDA is supported by data from the Phase 3 DUPLEX Study and Phase 2 DUET Study.
• The FDA has 60 days to decide whether to accept the application for review.
• Travere expects to receive notice regarding acceptance and the review timeline in the second quarter of 2025.
• If approved, FILSPARI could be the first FDA-approved treatment for FSGS, a rare kidney condition affecting over 40,000 patients in the U.S. and a similar number in Europe.
• The DUPLEX study, the largest interventional study in FSGS, showed clinically meaningful benefit at 108 weeks, including significant proteinuria reduction and a lower rate of end-stage kidney disease compared to the active control.
• The DUET study met its primary endpoint, demonstrating a greater than two-fold reduction in proteinuria compared to irbesartan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the sNDA submission and potential for FILSPARI to become the first approved treatment for FSGS. However, risks associated with regulatory approval and commercialization temper the optimism.

Positives

• The sNDA submission for FILSPARI represents a significant step towards providing a potential treatment option for FSGS patients.
• The DUPLEX study demonstrated clinically meaningful benefits, including significant proteinuria reduction and a lower rate of end-stage kidney disease.
• The DUET study showed a greater than two-fold reduction in proteinuria compared to irbesartan.
• FILSPARI was well-tolerated in clinical trials, with a safety profile comparable to the active control, irbesartan.

Negatives

• The DUPLEX study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment.

Risks

• There is no guarantee that the FDA will accept the sNDA for filing or grant priority review.
• There is no guarantee that the FDA will approve FILSPARI for FSGS on the anticipated timeline, or at all.
• The company faces risks related to the commercial launch of FILSPARI in IgAN, clinical study outcomes, market acceptance, manufacturing scale-up, and competition.
• The company may face challenges in raising additional funding for product development.
• Global and macroeconomic conditions, including health epidemics and pandemics, could disrupt clinical trials, commercialization, supply chain, and manufacturing operations.

Future Outlook

The company anticipates a decision from the FDA regarding the acceptance and review timeline of the sNDA in the second quarter of 2025 and hopes for approval of FILSPARI as the first treatment for FSGS.

Industry Context

The announcement is significant as there are currently no FDA-approved pharmacologic therapies for FSGS, highlighting a substantial unmet medical need. If approved, FILSPARI would be the first and only FDA-approved medicine indicated for FSGS.

Comparison to Industry Standards

• The DUPLEX study is the largest interventional study to date in FSGS, and the only study in FSGS against a maximally dosed active comparator.
• The Phase 2 DUET Study of sparsentan in FSGS met the primary efficacy endpoint for the combined treatment group, demonstrating a greater than two-fold reduction in proteinuria compared to irbesartan.

Stakeholder Impact

• Positive impact on FSGS patients if FILSPARI is approved, providing a much-needed treatment option.
• Potential positive impact on shareholders if FILSPARI achieves regulatory approval and commercial success.
• Potential positive impact on Travere Therapeutics employees through company growth and success.

Next Steps

• The FDA will review the sNDA and decide whether to accept it for review.
• The company expects to receive notice from the FDA regarding acceptance and the review timeline in the second quarter of 2025.
• The company will continue to work with the FDA throughout the review process.

Key Dates